Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
atopic dermatitis
Biotech
Apollo $15M bet on IL-18 antibody pays off with ph. 2 eczema win
Apollo’s $15 million bet on Avalo’s anti-IL-18 monoclonal antibody appears to have paid off after the candidate aced a dermatitis trial.
James Waldron
Sep 16, 2025 9:50am
Pfizer vet takes CEO post at new, phase 3-ready biotech
Sep 9, 2025 10:03am
Enveda harvests another $150M to advance nature-inspired drugs
Sep 4, 2025 9:14am
Sanofi phase 3 eczema win falls below analyst expectations
Sep 4, 2025 4:46am
Akeso scores twice in phase 3, tees up regulatory submission
Aug 25, 2025 1:37pm
AbbVie ends development of IL-1 asset in ulcerative colitis
Jul 31, 2025 12:32pm
